Otsuka Pakistan Limited resumes production after completing its annual maintenance, with shares rising 4.3%. Routine shutdown ensures operational efficiency and market reliability.

ABSTRACT: Introduction: Anaemia is one of the most common complications of Chronic Kidney Disease (CKD) and significantly impairs the quality of life of patients undergoing chronic haemodialysis. The ...

STOCKHOLM, Nov. 13, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi (lecanemab) has been approved for once every four weeks intravenous ...

The best haircuts are the ones that don’t require me to head back to the salon in a few weeks for a touch-up. IDC if it’s simple or ~basic~, I just hate constant trims, and even worse, spending hours ...

Panelists discuss how maintaining patients on effective single therapies for Crohn’s disease is preferable to switching between different mechanisms of action, while addressing access challenges ...

TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (BIIB) (Nasdaq ...

Background Blood blister-like aneurysms (BBAs) of the internal carotid artery are rare but high risk lesions that frequently re-rupture due to their fragile structure and dissecting pathology.

The U.S. Food and Drug Administration (FDA) has approved Leqembi Iqlik (lecanemab-irmb), an under-the-skin autoinjector formulation for maintenance dosing in early Alzheimer’s disease. The approval, ...

While the approval of Leqembi Iqlik bodes well for Biogen and Eisai’s planned application for a subcutaneous induction regimen next year, its financial impact remains “uncertain,” as potentially ...

NEW YORK – The US Food and Drug Administration has approved a subcutaneous version of Eisai and Biogen's anti-amyloid Alzheimer's disease drug Leqembi (lecanemab) as an ongoing maintenance treatment, ...